Formycon AG
XETRA:FYB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.2
57
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Formycon AG
Formycon AG
Cash & Cash Equivalents
Formycon AG
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formycon AG
XETRA:FYB
|
Cash & Cash Equivalents
€27m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash & Cash Equivalents
€11.7B
|
CAGR 3-Years
113%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Cash & Cash Equivalents
€131.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash & Cash Equivalents
€402.5m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash & Cash Equivalents
€218.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
194%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash & Cash Equivalents
€24.7m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-11%
|
|
Formycon AG
Glance View
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
See Also
What is Formycon AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
27m
EUR
Based on the financial report for Dec 31, 2023, Formycon AG's Cash & Cash Equivalents amounts to 27m EUR.
What is Formycon AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
30%
Over the last year, the Cash & Cash Equivalents growth was 175%. The average annual Cash & Cash Equivalents growth rates for Formycon AG have been -14% over the past three years , 30% over the past five years .
You don't have any saved screeners yet
